The Role of Angiotensin II Receptor 1 (AT1) Blockade in Cisplatin-Induced Nephrotoxicity in Rats: Gender-Related Differences

REFERENCES

• Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther. 2003;10(1):3–14.
   PubMedGoogle Scholar
• McGuinness SJ, Ryan MP. Mechanism of cisplatin nephrotoxicity in rat renal proximal tubule suspensions. Toxicol In Vitro. 1994;8(6):1203–1212.
   PubMedGoogle Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2:2490–2518.
   PubMed Web of Science ®Google Scholar
• Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007;81(7):495–504.
   PubMed Web of Science ®Google Scholar
• Wei Q, Wang MH, Dong Z. Differential gender differences in ischemic and nephrotoxic acute renal failure. Am J Nephrol. 2005;25(5):491–499.
   PubMedGoogle Scholar
• Ajith TA, Abhishek G, Roshny D, Sudheesh NP. Co-supplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp Toxicol Pathol. 2009;61(6):565–571.
   PubMedGoogle Scholar
• Appenroth D, Frob S, Kersten L, Splinter FK, Winnefeld K. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol. 1997;71(11):677–683.
   PubMed Web of Science ®Google Scholar
• Saleh S, El-Demerdash E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: Role of nitric oxide. Basic Clin Pharmacol Toxicol. 2005;97(2):91–97.
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM, Eissa MA, Kenawy SA, Mostafa N, Calvani M, Osman AM. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy. 2004;50(4):162–170.
   PubMedGoogle Scholar
• Uzunoglu S, Karagol H, Ozpuyan F, . Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats. Med Oncol. 2011;28(Suppl. 1):S690–S696.
   PubMedGoogle Scholar
• Goncalves AR, Fujihara CK, Mattar AL, . Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: Strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol. 2004;286(5): F945–F954.
   Google Scholar
• Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther. 2007;323(1):85–93.
   PubMedGoogle Scholar
• Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, Hande KR. The role of the renin-angiotensin system in cisplatin nephrotoxicity. Ren Fail. 1995;17(6):665–674.
   PubMed Web of Science ®Google Scholar
• Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy. 2009;55(6):399–406.
   PubMed Web of Science ®Google Scholar
• Stakisaitis D, Dudeniene G, Jankunas RJ, Grazeliene G, Didziapetriene J, Pundziene B. Cisplatin increases urinary sodium excretion in rats: Gender-related differences. Medicina (Kaunas). 2010;46(1):45–50.
   PubMedGoogle Scholar
• Sampson AK, Moritz KM, Jones ES, Flower RL, Widdop RE, Denton KM. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52(4):666–671.
   PubMedGoogle Scholar
• Hilliard LM, Nematbakhsh M, Kett MM, . Gender differences in pressure-natriuresis and renal autoregulation: Role of the angiotensin type 2 receptor. Hypertension. 2011;57(2):275–282.
   PubMed Web of Science ®Google Scholar
• Kaschina E, Angiotensin UT. AT1/AT2 receptors: Regulation, signalling and function. Blood Press. 2003;12(2):70–88.
   PubMed Web of Science ®Google Scholar
• Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens. 2005;14(1):67–71.
   PubMedGoogle Scholar
• de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52(3):415–472.
   PubMed Web of Science ®Google Scholar
• Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest. 1991;88(3):921–933.
   PubMedGoogle Scholar
• Perlegas D, Xie H, Sinha S, . The angiotensin type-2 receptor regulates smooth muscle growth and force generation in late fetal mouse development. Am J Physiol Heart Circ Physiol. 2004;288(1):H96–H102.
   Google Scholar
• Silva-Antonialli MM, Tostes RC, Fernandes L, . A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc Res. 2004;62(3):587–593.
   PubMed Web of Science ®Google Scholar
• Armando I, Jezova M, Juorio AV, . Estrogen upregulates renal angiotensin II AT(2) receptors. Am J Physiol Renal Physiol. 2002;283(5):F934–F943.
   PubMed Web of Science ®Google Scholar
• Nickenig G, Baumer AT, Grohe C, . Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97(22):2197–2201.
   PubMedGoogle Scholar
• Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1–7): An update. Regul Pept. 2000;91(1–3):45–62.
   PubMedGoogle Scholar
• Sullivan JC, Bhatia K, Yamamoto T, Elmarakby AA. Angiotensin (1–7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats. Hypertension. 2010;56(4):658–666.
   PubMedGoogle Scholar
• Miller JA, Cherney DZ, Duncan JA, . Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17(9):2554–2560.
   PubMedGoogle Scholar
• Souza dos Santos RA, Passaglio KT, Pesquero JB, Bader M, Simões E Silva AC. Interactions between angiotensin-(1–7), kinins, and angiotensin II in kidney and blood vessels. Hypertension. 2001;38(3):660–664.
   PubMedGoogle Scholar
• Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM. Angiotensin receptor blockers: Evidence for preserving target organs. Clin Cardiol. 2001;24(3):183–190.
   PubMedGoogle Scholar
• Ruster C, Wolf G. Renin–angiotensin–aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17(11):2985–2991.
   PubMed Web of Science ®Google Scholar
• Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int. 2005;67(3):799–812.
   PubMedGoogle Scholar
• Vazquez E, Coronel I, Bautista R, . Angiotensin II-dependent induction of AT(2) receptor expression after renal ablation. Am J Physiol Renal Physiol. 2005;288(1): F207–F213.
   Google Scholar
• Unger T. The angiotensin type 2 receptor: Variations on an enigmatic theme. J Hypertens. 1999;17(12 Pt. 2):1775–1786.
   PubMedGoogle Scholar
• Tauler P, Ferrer MD, Romaguera D, . Antioxidant response and oxidative damage induced by a swimming session: Influence of gender. J Sports Sci. 2008;26(12):1303–1311.
   PubMed Web of Science ®Google Scholar